Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8261)
All Articles published online
|
Publishing Process of This Article
|
Apr 21, 2014 (publication date) through Apr 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Nishida T, Tsujii M, Tanimura H, Tsutsui S, Tsuji S, Takeda A, Inoue A, Fukui H, Yoshio T, Kishida O, Ogawa H, Oshita M, Kobayashi I, Zushi S, Ichiba M, Uenoyama N, Yasunaga Y, Ishihara R, Yura M, Komori M, Egawa S, Iijima H, Takehara T. Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i15/4362.htm |
| Number | Citing Articles |
| 1 |
Takaharu Sasaki, Rei Saito, Midori Oyama, Tomoharu Takeuchi, Toru Tanaka, Hideshi Natsume, Mayumi Tamura, Yoichiro Arata, Tomomi Hatanaka. Galectin-2 Has Bactericidal Effects against Helicobacter pylori in a β-galactoside-Dependent Manner. International Journal of Molecular Sciences 2020; 21(8): 2697 doi: 10.3390/ijms21082697
|
| 2 |
Kazuhiro Mizukami, Masaaki Kodama, Masahide Fukuda, Yuka Hirashita, Koshiro Tsutsumi, Kensuke Fukuda, Ryo Ogawa, Kazuhisa Okamoto, Tadayoshi Okimoto, Kazunari Murakami. Comparison of the improvement in gastric mucosal tissue after Helicobacter pylori eradication between young and elderly people. Arab Journal of Gastroenterology 2023; 24(2): 98 doi: 10.1016/j.ajg.2023.01.005
|
| 3 |
Yoshimasa Saito, Hiroshi Serizawa, Yukako Kato, Masaru Nakano, Masahiko Nakamura, Hidetsugu Saito, Hidekazu Suzuki, Takanori Kanai. First-line eradication for <i>Helicobacter pylori</i>-positive gastritis by esomeprazole-based triple therapy is influenced by <i>CYP2C19</i> genotype. World Journal of Gastroenterology 2015; 21(48): 13548-13554 doi: 10.3748/wjg.v21.i48.13548
|
| 4 |
Tadayoshi Okimoto, Kazuhiro Mizukami, Ryo Ogawa, Kazuhisa Okamoto, Mitsutaka Shuto, Kensuke Fukuda, Masaaki Kodama, Kazunari Murakami. Esomeprazole- or rabeprazole-based triple therapy eradicated <i>Helicobacter pylori</i> comparably regardless of clarithromycin susceptibility and CYP2C19 genotypes. Journal of Clinical Biochemistry and Nutrition 2016; 59(2): 149 doi: 10.3164/jcbn.16-18
|
| 5 |
Kazunari Murakami. II. Present Status of <i>Helicobacter pylori</i> Eradication Therapy and Problems after Eradication. Nihon Naika Gakkai Zasshi 2017; 106(1): 16 doi: 10.2169/naika.106.16
|
| 6 |
Jing Fu, Zhongyuan Wu, Lijuan Zhang. Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part B. Progress in Molecular Biology and Translational Science 2019; 163: 487 doi: 10.1016/bs.pmbts.2019.03.005
|
| 7 |
Kazutake Oguma, Sadanori Kubo, Fumihiko Nozu, Hiroaki Shiraishi, Takeshi Yano, Shigeaki Aihara, Masaaki Matsukawa, Kazuhide Kumagai. A study of digestive symptoms before and after successful Helicobacter pylori eradication therapy. Progress of Digestive Endoscopy 2017; 91(1): 52 doi: 10.11641/pde.91.1_52
|
| 8 |
Shoko Ono, Mototsugu Kato, Soichi Nakagawa, Katsuhiro Mabe, Naoya Sakamoto. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. Helicobacter 2017; 22(3) doi: 10.1111/hel.12374
|
| 9 |
Gwang Ha Kim. Status ofHelicobacter pyloriEradication in Japan. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2017; 17(1): 4 doi: 10.7704/kjhugr.2017.17.1.4
|
| 10 |
Ariolana A dos Santos, Adriana A Carvalho. Pharmacological therapy used in the elimination of <italic>Helicobacter pylori</italic> infection: A review. World Journal of Gastroenterology 2015; 21(1): 139-154 doi: 10.3748/wjg.v21.i1.139
|
| 11 |
Negin Kashani, Amin Talebi Bezmin Abadi. Comment on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”. Gastroenterology Research and Practice 2018; 2018: 1 doi: 10.1155/2018/5173904
|
| 12 |
Yoen‐Young Chuah, Deng‐Chyang Wu, Seng‐Kee Chuah, Jyh‐Chin Yang, Tzong‐Hsi Lee, Hong‐Zen Yeh, Chan‐Lin Chen, Yu‐Hwa Liu, Ping‐I Hsu. Real‐world practice and Expectation of Asia‐Pacific physicians and patients in Helicobacter Pylori eradication (REAP‐HP Survey). Helicobacter 2017; 22(3) doi: 10.1111/hel.12380
|
| 13 |
Steven F. Moss, William D. Chey, Patrick Daniele, Corey Pelletier, Rinu Jacob, Gabriel Tremblay, Elizabeth Hubscher, Eckhard Leifke, Peter Malfertheiner. Brief communication: global temporal trends in the efficacy of clarithromycin-based regimens for the treatment of Helicobacter pylori infection. Therapeutic Advances in Gastroenterology 2023; 16 doi: 10.1177/17562848231167284
|
| 14 |
Komei Iwai, Tetsuji Azuma, Takatoshi Yonenaga, Yasuyuki Sasai, Kazutoshi Watanabe, Akihiro Obora, Fumiko Deguchi, Takao Kojima, Takaaki Tomofuji. Association between failed eradication of 7-day triple therapy for Helicobacter pylori and untreated dental caries in Japanese adults. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-54757-8
|
| 15 |
Sho Suzuki, Takuji Gotoda, Chika Kusano, Kunio Iwatsuka, Mitsuhiko Moriyama. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. American Journal of Gastroenterology 2016; 111(7): 949 doi: 10.1038/ajg.2016.182
|
| 16 |
Shinichiro Shinzaki, Toshimitsu Fujii, Shigeki Bamba, Maiko Ogawa, Taku Kobayashi, Masahide Oshita, Hiroki Tanaka, Keiji Ozeki, Sakuma Takahashi, Hiroki Kitamoto, Kazuhito Kani, Sohachi Nanjo, Takeshi Sugaya, Yuko Sakakibara, Toshihiro Inokuchi, Kazuki Kakimoto, Akihiro Yamada, Hisae Yasuhara, Yoko Yokoyama, Takuya Yoshino, Akira Matsui, Misaki Nakamura, Taku Tomizawa, Ryosuke Sakemi, Noriko Kamata, Toshifumi Hibi. Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease. Intestinal Research 2018; 16(4): 609 doi: 10.5217/ir.2018.00044
|
| 17 |
Soichiro Sue, Wataru Shibata, Tomohiko Sasaki, Hiroaki Kaneko, Kuniyasu Irie, Masaaki Kondo, Shin Maeda. Randomized trial of vonoprazan‐based versus proton‐pump inhibitor‐based third‐line triple therapy with sitafloxacin for Helicobacter pylori. Journal of Gastroenterology and Hepatology 2019; 34(4): 686 doi: 10.1111/jgh.14456
|
| 18 |
Peter Malfertheiner, Steven F. Moss, Patrick Daniele, Corey Pelletier, Rinu Jacob, Gabriel Tremblay, Elizabeth Hubscher, Eckhard Leifke, William D. Chey. Potassium-Competitive Acid Blocker and Proton Pump Inhibitor–Based Regimens for First-Line Helicobacter pylori Eradication: A Network Meta-Analysis. Gastro Hep Advances 2022; 1(5): 824 doi: 10.1016/j.gastha.2022.06.009
|
| 19 |
Amin Talebi Bezmin Abadi, Yeong Yeh Lee. Chinese <i>Helicobacter pylori</i> vaccine: Solution for an old challenge?. World Journal of Gastrointestinal Pharmacology and Therapeutics 2016; 7(3): 412-415 doi: 10.4292/wjgpt.v7.i3.412
|
| 20 |
Yoon Jin Choi, Yong Chan Lee, Jung Mogg Kim, Jin Il Kim, Jeong Seop Moon, Yun Jeong Lim, Gwang Ho Baik, Byoung Kwan Son, Hang Lak Lee, Kyoung Oh Kim, Nayoung Kim, Kwang Hyun Ko, Hye-Kyung Jung, Ki-Nam Shim, Hoon Jai Chun, Byung-Wook Kim, Hyuk Lee, Jie-Hyun Kim, Hyunsoo Chung, Sang Gyun Kim, Jae Young Jang. Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial. Gut and Liver 2022; 16(4): 535 doi: 10.5009/gnl220055
|
| 21 |
Soichiro Sue, Marina Ogushi, Isao Arima, Hirofumi Kuwashima, Satoshi Nakao, Makoto Naito, Kazuo Komatsu, Hiroaki Kaneko, Toshihide Tamura, Tomohiko Sasaki, Masaaki Kondo, Wataru Shibata, Shin Maeda. Vonoprazan‐ vs proton‐pump inhibitor‐based first‐line 7‐day triple therapy for clarithromycin‐susceptible Helicobacter pylori: A multicenter, prospective, randomized trial. Helicobacter 2018; 23(2) doi: 10.1111/hel.12456
|
| 22 |
Kazutake Oguma, Masashi Sato, Sadanori Kubo, Hiroaki Shiraish, Takeshi Yano, Shigeaki Aihara, Masaaki Matsukawa, Kazuhide Kumagai. A study of symptoms, eradication rates, and the degree of atrophy in patients with Helicobacter pylori-associated gastritis. Progress of Digestive Endoscopy 2018; 92(1): 50 doi: 10.11641/pde.92.1_50
|
| 23 |
Márcia Fernanda Correia Jardim Paz, Marcus Vinícius Oliveira Barros de Alencar, Rodrigo Maciel Paulino de Lima, André Luiz Pinho Sobral, Glauto Tuquarre Melo do Nascimento, Cristiane Amaral dos Reis, Maria do Perpetuo Socorro de Sousa Coêlho, Maria Luísa Lima Barreto do Nascimento, Antonio Luiz Gomes Júnior, Kátia da Conceição Machado, Ag-Anne Pereira Melo de Menezes, Rosália Maria Torres de Lima, José Williams Gomes de Oliveira Filho, Ana Carolina Soares Dias, Antonielly Campinho dos Reis, Ana Maria Oliveira Ferreira da Mata, Sônia Alves Machado, Carlos Dimas de Carvalho Sousa, Felipe Cavalcanti Carneiro da Silva, Muhammad Torequl Islam, João Marcelo de Castro e Sousa, Ana Amélia de Carvalho Melo Cavalcante. Pharmacological Effects and Toxicogenetic Impacts of Omeprazole: Genomic Instability and Cancer. Oxidative Medicine and Cellular Longevity 2020; 2020: 1 doi: 10.1155/2020/3457890
|
| 24 |
Su Young Kim, Duck Joo Choi, Jun-Won Chung. Antibiotic treatment for <italic>Helicobacter pylori</italic>: Is the end coming?. World Journal of Gastrointestinal Pharmacology and Therapeutics 2015; 6(4): 183-198 doi: 10.4292/wjgpt.v6.i4.183
|